isirv

Forthcoming Influenza and Antiviral Conferences

Previous Influenza and Antiviral Conferences

Antiviral Group virtual Conference on ‘Therapeutics for COVID-19’

Over 300 attended this three day Antiviral Group virtual Conference on ‘Therapeutics for COVID-19’ 6-8 October 2020, introduced by Sir Jeremy Farrar, Director of the Wellcome Trust, London, who set the scene for a comprehensive programme of talks and discussions of recent research on this urgent topic at a particularly crucial time in the pandemic.

Registered participants can access recordings of the conference here.

The programme document is available here.

Slides from oral presentations

• COVID-19 CLINICAL SPECTRUM, COMPLICATIONS, AND COINFECTIONS
• VIRAL REPLICATION KINETICS AND ANTIBODY RESPONSES
• IMMUNOPATHOGENESIS OF COVID-19
• PATHOGENESIS AND MANAGEMENT OF ARDS
• SOFOSBUVIR AND DACLATASVIR COMPARED TO STANDARD OF CARE IN THE TREATMENT OF PATIENTS WITH CORONAVIRUS INFECTION (COVID-19): A RANDOMISED CONTROLLED TRIAL
• INHIBITION OF SIRTUINS IS BROADLY EFFECTIVE AGAINST CORONAVIRUSES
• REPURPOSING OF CLINICALLY-APPROVED DRUGS FOR THE TREATMENT OF COVID-19
• FLUVOXAMINE FOR PREVENTION OF CLINICAL DETERIORATION IN EARLY COVID-19: RESULTS FROM A RANDOMIZED PLACEBO-CONTROLLED TRIAL
• PRE-CLINICAL MODELS FOR DOWNSELECTING CANDIDATES
• CONVALESCENT PLASMA AND POLYCLONAL ANTIBODIES
• MONOCLONAL ANTIBODIES
• COMPLETE MAPPING OF MUTATIONS TO THE SARS-COV-2 SPIKE RECEPTOR-BINDING DOMAIN THAT ESCAPE ANTIBODY RECOGNITION
• BLOCKAGE OF CATHEPSIN L ACTIVITY BY SLV213, A NOVEL CYSTEINE PROTEASE INHIBITOR, PREVENTS SARS-COV-2 VIRAL ENTRY
• EFFECT OF JAK INHIBITOR TREATMENT ON CLINICAL OUTCOME, LUNG PATHOLOGY, AND VIRAL LOAD IN A MOUSE MODEL OF PATHOGENIC SARS-COV-2 INFECTION
• TREATMENT OF SEVERE COVID-19 WITH LOW-DOSE SELINEXOR: DEMONSTRATION OF ANTI-VIRAL AND ANTI-INFLAMMATORY ACTIVITIES IN A RANDOMIZED, INTERNATIONAL, MULTICENTER, PLACEBO-CONTROLLED PHASE 2 CLINICAL TRIAL
• MARGINAL EFFECT OF GC-376 AS A SARS-COV-2 ANTIVIRAL IN THE K18 hACE2 TRANSGENIC MOUSE MODEL
• A PHASE 2 STUDY OF LERONLIMAB FOR MILD TO MODERATE CORONAVIRUS DISEASE 2019 (COVID-19)
• SOLIDARITY TRIAL & LESSONS LEARNED
• REMDESIVIR
• EIDD-2801
• FAVIPIRIVIR
• JAK INHIBITORS
• TOCILIZUMAB IN COVID 19 - UPDATE
• OPERATION WARP SPEED THERAPEUTICS DEVELOPMENT
• DISCUSSION ON CLINICAL TRIAL ENDPOINTS

E-posters (click here for the list)

• Geographic correlation between the number of COVID-19 cases and the number of overseas travelers in Japan, January-February 2020
• Risk factors of viral RNAaemia and its association with clinical prognosis among patients with severe COVID-19
• Study on the Diagnostic Value of Blood Inflammatory Indicators in COVID-19
• A Rapid Review of the Asymptomatic Proportion of PCR-Confirmed SARS-CoV-2 Infections in Community Settings
• The SymptomSurvey: Patient and Caretaker Perspectives on COVID-19 Symptom Severity and the Expected Impact of Antivirals and Vaccines
• Understanding patients’ acceptability of self-collection of various clinical specimens to inform clinical diagnosis of COVID-19
• Quantitative proteomics characterization of respiratory viruses-exposed human primary T cells reveals host-pathogen interactions and therapy targets
• Transcriptional profiling of immune and inflammatory responses in the context of SARS-CoV-2 fungal superinfection in a human airway epithelial model
• Establishment of a novel real time PCR method to detect live SARS-CoV-2 in clinical samples
• The role of serological diagnosis in the study of the COVID-19 pathogenesis
• Characterization of spike activation and temperature dependence of SARS-CoV-2 and other human coronaviruses
• ICAM3 is a likely receptor for SARS CoV2 Entry
• Searching for antiviral strategies against a broad range of beta-CoV: Spike and Polymerase proteins as promising anti-CoV targets.
• Antiviral potential of distinct heparins against SARS-CoV-2 in vitro
• Guanosine as RNA Replication Blocker for Therapeutic Treatment of COVID 19
• AT-527, the oral prodrug of a guanosine nucleotide analog, is a potent in vitro inhibitor of SARS-CoV-2
• Plasma and tissue disposition of AT-527 and its active triphosphate metabolite in monkeys: implications for dose selection for patients with COVID-19
• Pre-planned meta-analysis of randomised trials of sofosbuvir-daclatasvir, to evaluate clinical benefits and survival
• Interpreting in-vitro data for sofosbuvir against SARS-CoV-2: cell lineage is key
• The in vitro antiviral activity of the anti-hepatitis C virus drugs daclatasvir and sofosbuvir against SARS-CoV-2.
• Role of 1’-Ribose Cyano Substitution for Remdesivir to Effectively Inhibit Nucleotide Addition and Proofreading in SARS-CoV-2 Viral RNA Replication
• Betulonic Acid Derivatives Interfering with Coronavirus Replication via the Nsp15 Endoribonuclease
• A Broad Inhibitor of Coronavirus Replication Acting via the Nsp15 Endoribonuclease
• Evaluation of SARS-CoV-2 3C-like protease inhibitors using self-assembled monolayer desorption ionization mass spectrometry
• Broad-spectrum antiviral activity of naproxen: from Influenza A to SARS-CoV2 Coronavirus
• Long-Acting Intramuscular Injection of Niclosamide as a Broad Host-Directed Therapeutic Against SARS-CoV-2 and Other Viral Infections
• Acute, Suprapharmacologic Dexamethasone Mobilizes Natural Killer T and Cytotoxic T cells for COVID-19 ARDS
• Low-to-moderate dose corticosteroids Treatment in Hospitalized Adults With COVID-19

Congratulations to the awardees of Best Oral Presentation and Best Poster Presentation.

See you at our next conference!